“First of its kind” manufacturing campus to bring 500 jobs to Ireland
pharmafile | September 19, 2016 | News story | Manufacturing and Production, Sales and Marketing | GE Healthcare, Ireland, manufacturing
Biopharma firm GE Healthcare has made a major investment to create a ‘BioPark’ in Ringaskiddy, Ireland, set to generate 500 new jobs.
The new manufacturing campus, named KUBio, claims to be the “first of its kind” in Europe: it will host a number of new companies, will provide prefabricated, off-the-shelf bio-manufacturing facilities, owned and run by GE customers, and will serve as focal point for further investment in next-generation biopharmaceutical manufacturing in Ireland.
The project comprises four KUBio sites, each owned by a separate company and making up 400 of the expected 500 jobs. GE will employ the remaining 100 on-site.
“The choice of Ireland for this strategically important investment by GE is a significant win,” commented Martin Shanahan, CEO of IDA.“The biopharmaceutical manufacturing campus will greatly assist IDA Ireland win additional bio-manufacturing investments by acting as a catalyst to attract new innovator drug companies and to transition and grow existing operations.”
The project is due to begin within 12 months.
Matt Fellows
Related Content

Brenntag and dsm-firmenich expand biopharma vitamin partnership
Brenntag Pharma and dsm-firmenich have entered a long-term global distribution partnership covering GMP-grade vitamins for …

Phoenix Labs acquires Kent Pharma
Phoenix Labs has acquired UK pharmaceutical distributor Kent Pharma from private equity firm Duke Street, …

Thermo Fisher opens new distribution centre in Ireland
Thermo Fisher Scientific has announced the opening of a new 70,000sqft distribution centre in Bracetown, …





